Amisulpride, Asenapine, Lurasidone, Brexpiprazole, Cariprazine

Jonathan M. Meyer; Stephen M. Stahl

doi:10.1017/9781009002103.020

17 - Amisulpride, Asenapine, Lurasidone, Brexpiprazole, Cariprazine

Published online by Cambridge University Press: 19 October 2021

Jonathan M. Meyer and

Stephen M. Stahl

Show author details

Jonathan M. Meyer: Affiliation:
University of California, San Diego
Stephen M. Stahl: Affiliation:
University of California, Riverside and San Diego

Book contents

Get access

Summary

The psychopharmacology field is moving toward a mechanism-based nomenclature to replace outmoded descriptors of molecules with multiple pharmacological properties. In addition to publications covering these efforts [15–17], a Neuroscience-Based Nomenclature website was created (https://nbn2r.com) where one can download a free smartphone app, and which posts twice-yearly glossary updates in May and September. For the sake of simplicity, the term second-generation antipsychotic (SGA) will be used in this chapter, but the antipsychotics described herein have a range of pharmacologic properties, and a wide variety of kinetic profiles. Moreover, with the exception of transdermal asenapine and cariprazine, the SGAs presented in this chapter represent a group that are generally available worldwide.

Type: Chapter
Information: The Clinical Use of Antipsychotic Plasma Levels
Stahl's Handbooks
, pp. 337 - 371

DOI: https://doi.org/10.1017/9781009002103.020 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Subscription

Individual access

Subscriptions are only available for individuals and not institutional access. Subscribe now

References

Sparshatt, A., Taylor, D., Patel, M. X., et al. (2009). Amisulpride – dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring. Acta Psychiatr Scand, 120, 416–428.Google Scholar

Ishigooka, J., Iwashita, S., Higashi, K., et al. (2018). Pharmacokinetics and safety of brexpiprazole following multiple-dose administration to Japanese patients with schizophrenia. J Clin Pharmacol, 58, 74–80.Google Scholar

Periclou, A., Willavize, S., Jaworowicz, D., et al. (2020). Relationship between plasma concentrations and clinical effects of cariprazine in patients with schizophrenia or bipolar mania. Clin Transl Sci, 13, 362–371.Google Scholar

Loebel, A., Silva, R., Goldman, R., et al. (2016). Lurasidone dose escalation in early nonresponding patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry, 77, 1672–1680.Google Scholar

FDA Center for Drug Evaluation and Research (2015). Cariprazine pharmacology/toxicology NDA review and evaluation.Google Scholar

Findling, R. L., Goldman, R., Chiu, Y. Y., et al. (2015). Pharmacokinetics and tolerability of lurasidone in children and adolescents with psychiatric disorders. Clin Ther, 37, 2788–2797.Google Scholar

Schmitt, U., Abou El-Ela, A., Guo, L. J., et al. (2006). Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp). J Neural Transm (Vienna), 113, 787–801.Google Scholar

O’Brien, F. E., Dinan, T. G., Griffin, B. T., et al. (2012). Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings. Br J Pharmacol, 165, 289–312.Google Scholar

Bartlett, J. A. and van der Voort Maarschalk, K. (2012). Understanding the oral mucosal absorption and resulting clinical pharmacokinetics of asenapine. AAPS PharmSciTech, 13, 1110–1115.Google Scholar

Allergan USA Inc. (2017). Saphris package insert. Irvine, CA.Google Scholar

Noven Therapeutics LLC (2020). Secuado package insert. Miami, FL.Google Scholar

Otsuka America Pharmaceutical Inc. (2020). Rexulti package insert. Rockville, MD.Google Scholar

Allergan USA Inc. (2019). Vraylar package insert. Madison, NJ.Google Scholar

Nakamura, T., Kubota, T., Iwakaji, A., et al. (2016). Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). Drug Des Devel Ther, 10, 327–338.Google Scholar

Blier, P., Oquendo, M. A., and Kupfer, D. J. (2017). Progress on the Neuroscience-Based Nomenclature (NbN) for Psychotropic Medications. Neuropsychopharmacology, 42, 1927–1928.Google Scholar

Uchida, H. (2018). Neuroscience-based Nomenclature: what is it, why is it needed, and what comes next? Psychiatry Clin Neurosci, 72, 50–51.Google Scholar

Siafis, S., Davis, J. M., and Leucht, S. (2020). Antipsychotic drugs: from ‘major tranquilizers’ to Neuroscience-based-Nomenclature. Psychol Med, 1–3.Google Scholar

Correll, C. U., Jain, R., Meyer, J. M., et al. (2019). Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation. Neuropsychiatr Dis Treat, 15, 2537–2550.Google Scholar

Vanda Pharmaceuticals Inc. (2018). Fanapt package insert. Washington, DC.Google Scholar

Komossa, K., Rummel-Kluge, C., Hunger, H., et al. (2009). Sertindole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev, CD006752.Google Scholar

Beedham, C., Miceli, J. J., and Obach, R. S. (2003). Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol, 23, 229–232.Google Scholar

Roerig Division of Pfizer Inc. (2020). Geodon package insert. New York.Google Scholar

Asmal, L., Flegar, S. J., Wang, J., et al. (2013). Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev, CD006625.Google Scholar

Vanasse, A., Blais, L., Courteau, J., et al. (2016). Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: a real-world observational study. Acta Psychiatr Scand, 134, 374–384.Google Scholar

Intra-Cellular Therapies Inc. (2019). Caplyta package insert. New York.Google Scholar

Vyas, P., Hwang, B. J., and Brasic, J. R. (2019). An evaluation of lumateperone tosylate for the treatment of schizophrenia. Expert Opin Pharmacother, 30, 1–7.Google Scholar

Meyer, J. M. (2020). Lumateperone for schizophrenia. Curr Psychiatr, 19, 33–39.Google Scholar

Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., et al. (2019). Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet, 394, 939–951.Google Scholar

Kahn, R. S., Winter van Rossum, I., Leucht, S., et al. (2018). Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry, 5, 797–807.Google Scholar

Delcker, A., Schoon, M. L., Oczkowski, B., et al. (1990). Amisulpride versus haloperidol in treatment of schizophrenic patients – results of a double-blind study. Pharmacopsychiatry, 23, 125–130.Google Scholar

Abbas, A. I., Hedlund, P. B., Huang, X.-P., et al. (2009). Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology, 205, 119–128.Google Scholar

Meyer, J. M., Loebel, A. D., and Schweizer, E. (2009). Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs, 18, 1715–1726.Google Scholar

Meyer, J. M. (2018). Pharmacotherapy of psychosis and mania. In Brunton, L. L., Hilal-Dandan, R. and Knollmann, B. C., eds., Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 13th edn. Chicago, IL: McGraw-Hill, pp. 279–302.Google Scholar

Schoemaker, H., Claustre, Y., Fage, D., et al. (1997). Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther, 280, 83–97.Google Scholar

Stahl, S. M. (2017). Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes. CNS Spectr, 22, 375–384.Google Scholar

Kahn, R. S., Fleischhacker, W. W., Boter, H., et al. (2008). Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet, 371, 1085–1097.Google Scholar

Hartter, S., Huwel, S., Lohmann, T., et al. (2003). How does the benzamide antipsychotic amisulpride get into the brain? – An in vitro approach comparing amisulpride with clozapine. Neuropsychopharmacology, 28, 1916–1922.Google Scholar

Wang, R., Sun, X., Deng, Y. S., et al. (2018). ABCB1 1199G > A polymorphism impacts transport ability of P-gp-mediated antipsychotics. DNA Cell Biol, 37, 325–329.+A+polymorphism+impacts+transport+ability+of+P-gp-mediated+antipsychotics.+DNA+Cell+Biol,+37,+325–329.>Google Scholar

Arrowtex Pharmaceuticals (2019). Amisulpride package insert. Macquarie Park, NSW, Australia.Google Scholar

Bergemann, N., Kopitz, J., Kress, K. R., et al. (2004). Plasma amisulpride levels in schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol, 14, 245–250.Google Scholar

Muller, M. J., Eich, F. X., Regenbogen, B., et al. (2009). Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder. J Psychopharmacol, 23, 278–286.Google Scholar

Schoretsanitis, G., Kane, J. M., Correll, C. U., et al. (2020). Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology (ASCP) and the Therapeutic Drug Monitoring (TDM) Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP). J Clin Psychiatry, 81, https://doi.org/10.4088/JCP.4019cs13169.Google Scholar

Puech, A., Fleurot, O., and Rein, W. (1998). Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. Acta Psychiatr Scand, 98, 65–72.Google Scholar

Muller, M. J., Regenbogen, B., Hartter, S., et al. (2007). Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia. J Psychiatr Res, 41, 673–679.Google Scholar

Mota, N. E., Lima, M. S., and Soares, B. G. (2002). Amisulpride for schizophrenia. Cochrane Database Syst Rev, 2002, CD001357.Google Scholar

Linden, M., Scheel, T., and Xaver Eich, F. (2004). Dosage finding and outcome in the treatment of schizophrenic inpatients with amisulpride: results of a drug utilization observation study. Hum Psychopharmacol, 19, 111–119.Google Scholar

Shahid, M., Walker, G. B., Zorn, S. H., et al. (2009). Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol, 23, 65–73.Google Scholar

Citrome, L. (2014). Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol, 10, 893–903.Google Scholar

Vieta, E. and Montes, J. M. (2018). A review of asenapine in the treatment of bipolar disorder. Clin Drug Investig, 38, 87–99.Google Scholar

El-Mallakh, R. S., Nuss, S., Gao, D., et al. (2020). Asenapine in the treatment of bipolar depression. Psychopharmacol Bull, 50, 8–18.Google Scholar

Koytchev, R., Alken, R. G., McKay, G., et al. (1996). Absolute bioavailability of oral immediate and slow release fluphenazine in healthy volunteers. Eur J Clin Pharmacol, 51, 183–187.Google Scholar

Andree, B., Halldin, C., Vrijmoed-de Vries, M., et al. (1997). Central 5-HT2A and D2 dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men. Psychopharmacology, 131, 339–345.Google Scholar

Carrithers, B. and El-Mallakh, R. S. (2020). Transdermal asenapine in schizophrenia: a systematic review. Patient Prefer Adherence, 14, 1541–1551.Google Scholar

Seager, H. (1998). Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol, 50, 375–382.Google Scholar

Pillinger, T., McCutcheon, R. A., Vano, L., et al. (2020). Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry, 7, 64–77.Google Scholar

Citrome, L. (2014). Asenapine review, part II: clinical efficacy, safety and tolerability. Expert Opin Drug Saf, 13, 803–830.Google Scholar

Dogterom, P., Riesenberg, R., de Greef, R., et al. (2018). Asenapine pharmacokinetics and tolerability in a pediatric population. Drug Des Develop Ther, 12, 2677–2693.Google Scholar

de Greef, R., Maloney, A., Olsson-Gisleskog, P., et al. (2011). Dopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms. AAPS Journal, 13, 121–130.Google Scholar

Food and Drug Administration Center for Drug Evaluation and Research (2009). Asenapine medical review.Google Scholar

Hiemke, C., Bergemann, N., Clement, H. W., et al. (2018). Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry, 51, 9–62.Google Scholar

Chapel, S., Hutmacher, M. M., Haig, G., et al. (2009). Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation. J Clin Pharmacol, 49, 1297–1308.Google Scholar

Ward, H. B., Yudkoff, B. L., and Fromson, J. A. (2019). Lurasidone malabsorption following bariatric surgery: a case report. J Psychiatr Pract, 25, 313–317.Google Scholar

Baldessarini, R. J., Tondo, L., and Vazquez, G. H. (2019). Pharmacological treatment of adult bipolar disorder. Mol Psychiatry, 24, 198–217.Google Scholar

Sunovion Pharmaceuticals Inc. (2019). Latuda package insert. Marlborough, MA.Google Scholar

Wong, D. F., Kuwabara, H., Brašicć, J. R., et al. (2013). Determination of dopamine D2 receptor occupancy by lurasidone using positron emission tomography in healthy male subjects. Psychopharmacology, 229, 245–252.Google Scholar

Potkin, S. G., Keator, D. B., Kesler-West, M. L., et al. (2014). D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder. CNS Spectr, 19, 176–181.Google Scholar

Maeda, K., Lerdrup, L., Sugino, H., et al. (2014). Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin–dopamine activity modulator. J Pharmacol Exp Ther, 350, 605–614.Google Scholar

Maeda, K., Sugino, H., Akazawa, H., et al. (2014). Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin–dopamine activity modulator. J Pharmacol Exp Ther, 350, 589–604.Google Scholar

Tadori, Y., Forbes, R. A., McQuade, R. D., et al. (2011). In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors. Eur J Pharmacol, 668, 355–365.Google Scholar

McEvoy, J. and Citrome, L. (2016). Brexpiprazole for the treatment of schizophrenia: a review of this novel serotonin–dopamine activity modulator. Clin Schizophr Relat Psychoses, 9, 177–186.Google Scholar

Ward, K. and Citrome, L. (2019). Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy. Neuropsychiatr Dis Treat, 15, 247–257.Google Scholar

Girgis, R. R., Forbes, A., Abi-Dargham, A., et al. (2020). A positron emission tomography occupancy study of brexpiprazole at dopamine D2 and D3 and serotonin 5-HT_1A and 5-HT_2A receptors, and serotonin reuptake transporters in subjects with schizophrenia. Neuropsychopharmacology, 45, 786–792.Google Scholar

Takeuchi, H. and Remington, G. (2013). A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder. Psychopharmacology (Berl), 228, 175–185.Google Scholar

Wong, D. F., Malikaarjun, S., Raoufinia, A., et al. (2011). 619. A phase I, open-label PET study of the pharmacokinetics, tolerability and D2/D3 striatal occupancy of single-dose oral OPC-34712 in healthy subjects. Biol Psychiatry, 69, 187s.Google Scholar

Food and Drug Administration Center for Drug Evaluation and Research (2015). Cariprazine pharmacology/toxicology NDA review and evaluation.Google Scholar

Girgis, R. R., Slifstein, M., D’Souza, D., et al. (2016). Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO. Psychopharmacology (Berl), 233, 3503–3512.Google Scholar

Otsuka America Pharmaceutical Inc. (2020). Abilify package insert. Rockville, MD.Google Scholar

Németh, G., Laszlovszky, I., Czobor, P., et al. (2017). Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet, 389, 1103–1113.Google Scholar

Ragguett, R. M. and McIntyre, R. S. (2019). Cariprazine for the treatment of bipolar depression: a review. Expert Rev Neurother, 19, 317–323.Google Scholar